Table 1.

Biological and clinical characteristics of the CLL cohort according to TP53 mutation status

Characteristics at CLL diagnosisTP53 wild-typeTP53 mutatedP
Biological variables at diagnosis
    IGHV homology ≥98%99/272 (36.4%)16/31 (51.6%)0.098
    Normal FISH77/269 (28.6%)2/28 (7.1%)0.014
    Number of FISH lesions >136/269 (13.4%)13/28 (46.4%)<0.001
    del13q14135/269 (50.2%)16/28 (57.1%)0.483
    +1256/269 (20.8%)4/28 (14.3%)0.413
    del11q22-q2323/269 (8.6%)1/28 (3.6%)0.712
    del17p1316/269 (5.9%)18/28 (64.3%)<0.001
    CD38 ≥30%81/272 (29.8%)11/29 (37.9%)0.365
    ZAP70 ≥20%100/241 (41.5%)13/26 (50.0%)0.404
Clinical variables at diagnosis
    Age (y)68 (59-73)67 (58-77)0.847
    Age >65 y160/277 (57.8%)14/31 (54.8%)0.755
    Male147/277 (53.1%)17/31 (54.8%)0.851
    Binet B-C62/277 (22.4%)15/31 (48.4%)0.002
    Nodal areas ≥342/276 (15.2%)9/31 (29.0%)0.049
    Splenomegaly47/276 (17.0%)8/31 (25.8%)0.227
    Lymphocytes > 20 × 109/L74/277 (26.7%)8/31 (25.8%)0.914
    Hemoglobin <13 g/dL79/276 (28.6%)13/31 (41.9%)0.125
    Platelets <150 × 109/L64/276 (23.2%)15/31 (48.4%)0.002
    β2-Microglobulin > 2.5 mg/L108/252 (42.9%)17/27 (63.0%)0.046
    LDH >1× upper limit of normal50/269 (18.6%)10/31 (32.3%)0.072
Treatment
    Lines2 (1-3)3 (1-4)0.205
    Lines >240/119 (33.6%)12/22 (54.5%)0.062
    Fludarabine-based74/119 (62.2%)14/22 (63.6%)0.897
  • NOTE: The 25th to 75th percentiles are reported in parentheses for continuous variables.